Doctors should be cautious about giving steroids to patients suffering from COVID-19.
In its updated clinical guidelines for treating coronavirus, the government has stated just
days after its task force’s head expressed regret overusing the medication during its second
phase.
The new guidelines state that steroids and other drugs may raise the chance of secondary
infection, such as black fungus, also known as invasive mucormycosis, when taken in too
early or at a higher dosage or for a longer time than is required.
Indicating the dosages for the medications if required for three types of infections “mild,
moderate, severe and moderate” The guidelines stated that if the cough continues for more
than 2 to 3 weeks, patients must examine for the presence of tuberculosis as well as other
illnesses.
At a news conference this week, NITI Aayog Member (Health) and head of the Covid Task
Force, Dr. V K Paul, expressed concerns about the “overuse of and abuse” of steroids,
among other drugs.
Following the updated guidance, the upper respiratory tract symptoms with no sensation of
breathing becoming short or hypoxia are classified as a mild illness.
They are advised to stay at home and receive care and isolation.
People who suffer from mild Covid should seek medical treatment should they experience
difficulties respiration, high-grade fever, or a severe cough that lasts more than five days.
Patients who experience breathlessness, with the oxygen saturation fluctuating between 90
and 93 percent, may be admitted to the hospital and categorized as moderate cases.
These patients must receive oxygen therapy.
A respiratory rate of more than 30 per minute, breathing problems, or oxygen saturation
below 90% in the air in the room should be considered a severe illness.
According to the note, patients should be taken to an ICU since they’ll need respiratory
assistance.
Patients with these conditions should be placed on respiration support.
In addition, the use of non-invasive ventilators (NIV), either via a face mask or helmet
interface subject to availability – can be considered for patients who have increased oxygen
demands when breathing capacity is not as good.
The updated guidelines continue to advocate an emergency usage authorization (EUA) or
non-label use of remdesivir for patients suffering from “moderate to serious” disease or no
hepatic or renal impairment within ten days after the first onset of any symptoms.
The FDA warned against using the drug in patients who do not receive oxygen support or
have in-home settings.
Following these guidelines, EUA and off-label usage of drug tocilizumab may also be
considered when there is a severe illness, ideally within 24-48 hours of the first sign of
severe disease or in the intensive treatment units (ICU) admittance.
They stated that Tocilizumab could be considered in those with elevated inflammation
markers and who aren’t improving despite treatment with steroids, even if there is no
evidence of fungal, bacterial, or tubercular infections.
People over the age of 60 or who suffer from hypertension, cardiovascular disease, diabetic
artery disease, or other immunocompromised diseases that include HIV active tuberculosis,
chronic kidney or cerebrovascular disease, liver diseases, or obese people are at risk of
developing severe illness and death as per the guidelines.
